Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab

Int J Dermatol. 2020 Aug;59(8):e267-e268. doi: 10.1111/ijd.15008. Epub 2020 Jun 18.

Authors

Paola Facheris^{1

2}, Mario Valenti^{1

2}, Giulia Pavia^{1

2}, Luigi Gargiulo^{1

2}, Alessandra Narcisi¹, Antonio Costanzo^{1

2}, Riccardo G Borroni^{1

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
² Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, MI, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Betacoronavirus / immunology*
Betacoronavirus / isolation & purification
Brugada Syndrome / complications
COVID-19
COVID-19 Drug Treatment
COVID-19 Testing
Ceftriaxone / therapeutic use
Clinical Laboratory Techniques / methods
Continuous Positive Airway Pressure
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy
Coronavirus Infections / immunology*
Coronavirus Infections / therapy
Coronavirus Infections / virology
Humans
Hydroxychloroquine / therapeutic use
Lung Diseases, Interstitial / diagnosis
Lung Diseases, Interstitial / immunology*
Lung Diseases, Interstitial / therapy
Lung Diseases, Interstitial / virology
Male
Middle Aged
Nasopharynx / virology
Pandemics
Pneumonia, Viral / diagnosis
Pneumonia, Viral / immunology*
Pneumonia, Viral / therapy
Pneumonia, Viral / virology
Psoriasis / complications
Psoriasis / drug therapy*
Psoriasis / immunology
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Hydroxychloroquine
Ceftriaxone
ixekizumab